<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418353</url>
  </required_header>
  <id_info>
    <org_study_id>20024615</org_study_id>
    <nct_id>NCT00418353</nct_id>
  </id_info>
  <brief_title>Antenatal Betamethasone Compared to Dexamethasone - &quot;BETACODE TRIAL&quot;</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <brief_summary>
    <textblock>
      Antenatal corticosteroids result in substantial decrease in neonatal morbidity and mortality&#xD;
      by specifically reducing the risk of respiratory distress syndrome, intraventricular&#xD;
      hemorrhage and neonatal death among premature infants. No human randomized study has formally&#xD;
      compared betamethasone and dexamethasone, the preferred corticosteroids for antenatal&#xD;
      therapy, with regards to their effectiveness in reducing neonatal morbidities and mortality.&#xD;
      Our objective was to compare betamethasone with dexamethasone in terms of effectiveness in&#xD;
      reducing perinatal morbidities and mortality among preterm infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We conducted a double blind placebo-controlled randomized trial of antenatal betamethasone&#xD;
      compared to dexamethasone among women at risk of preterm deliveries at Stony Brook University&#xD;
      Hospital from August 1, 2002 through July 31, 2004. We excluded women with clinical&#xD;
      chorioamnionitis, major fetal structural anomalies, fetal chromosomal abnormalities, prior&#xD;
      antenatal steroid exposure, and use of betamethasone or dexamethasone for other medical&#xD;
      indications, quadruplets and higher order multiple gestation and those who declined&#xD;
      enrollment. Consenting women were randomly allocated to one of two groups by the Pharmacy&#xD;
      using computer generated random numbers. The statistical analysis was performed in accordance&#xD;
      of the intention-to-treat principle. Student t test, Chi square and Fisher exact test were&#xD;
      used for analysis. A P value of &lt; .05 was considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date>April 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory distress syndrome</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraventricular hemorrhage</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal mortality</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Periventricular leukomalacia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal sepsis</measure>
  </secondary_outcome>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Intraventricular Hemorrhage</condition>
  <condition>Neonatal Mortality</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone(Celestone soluspan) and Dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women in preterm labor with intact membranes&#xD;
&#xD;
          -  Women with preterm premature rupture of membranes&#xD;
&#xD;
          -  Women been delivered for fetal and maternal indications&#xD;
&#xD;
          -  Gestational age between 24 and 33 6/7 weeks'.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical chorioamnionitis&#xD;
&#xD;
          -  known major fetal structural anomalies,&#xD;
&#xD;
          -  known fetal chromosomal abnormalities,&#xD;
&#xD;
          -  prior antenatal steroid exposure,&#xD;
&#xD;
          -  quadruplets and higher order multiple gestation&#xD;
&#xD;
          -  Women who declined enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew A Elimian, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>117913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>January 2, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>January 2, 2007</last_update_submitted>
  <last_update_submitted_qc>January 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2007</last_update_posted>
  <keyword>Antenatal corticosteroids</keyword>
  <keyword>Betamethasone</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Premature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone acetate phosphate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

